Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
Frederick S. Barrett, Matthew W Johnson, Roland R. Griffiths
Journal of Psychopharmacology October 6, 2015 DOI: 10.1177/0269881115609019 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Validation study using pooled data from five laboratory experiments Peer reviewed |
|---|---|
| Sample size | 184 |
| Population | Participants in controlled laboratory experiments receiving a moderate to high oral dose of psilocybin |
| Intervention | psilocybin |
| Dose | at least 20 mg/70 kg |
| Topics | Mysticism Psilocybin Mystical experience |
| Keywords | Structural equation modeling Hallucinogen Confirmatory factor analysis Clinical psychology |
| Citations | 634 |
| Key findings | The MEQ30 is a reliable and valid measure of mystical-type experiences, and its scores positively predict persisting changes in attitudes, behavior, and well-being attributed to psilocybin experiences. |
Abstract
The 30-item revised Mystical Experience Questionnaire (MEQ30) was previously developed within an online survey of mystical-type experiences occasioned by psilocybin-containing mushrooms. The rated experiences occurred on average eight years before completion of the questionnaire. The current paper validates the MEQ30 using data from experimental studies with controlled doses of psilocybin. Data were pooled and analyzed from five laboratory experiments in which participants ( n=184) received a moderate to high oral dose of psilocybin (at least 20 mg/70 kg). Results of confirmatory factor analysis demonstrate the reliability and internal validity of the MEQ30. Structural equation models demonstrate the external and convergent validity of the MEQ30 by showing that latent variable scores on the MEQ30 positively predict persisting change in attitudes, behavior, and well-being attributed to experiences with psilocybin while controlling for the contribution of the participant-rated intensity of drug effects. These findings support the use of the MEQ30 as an efficient measure of individual mystical experiences. A method to score a “complete mystical experience” that was used in previous versions of the mystical experience questionnaire is validated in the MEQ30, and a stand-alone version of the MEQ30 is provided for use in future research.
In the evidence
This study is part of the evidence base for 2 syntheses in the library. Here is how each one recorded it.
-
The MEQ30 showed reliability and validity, and its latent scores positively predicted persisting changes in attitudes, behavior, and well-being attributed to psilocybin.
Synthesized
-
State of the evidence: Mysticism Supports
The 30-item Mystical Experience Questionnaire showed reliability and validity, and its latent scores positively predicted persisting changes in attitudes, behavior, and well-being attributed to psilocybin.
Synthesized
Comparable studies
Other experimental studies on mystical experience, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Alterations of consciousness and mystical-type experiences after acute LSD in humans Participants in a study on acute LSD effects | 2016 | Experimental study | |
| Mystical Experience in the Lab | 2014 | Experimental study | |
| Exploring Emptiness and its Effects on Non-attachment, Mystical Experiences, and Psycho-spiritual Wellbeing: A Quantitative and Qualitative Study of Advanced Meditators. Advanced Buddhist meditators | 2019 | Within-subjects experimental design with qualitative analysis | n = 25 |
| Expectancies for Cannabis-Induced Emotional Breakthrough, Mystical Experiences and Changes in Dysfunctional Attitudes: Perceptions of the Potential for Cannabis-Assisted Psychotherapy for Depression Cannabis users | 2022 | Survey-based experimental study | n = 1,000 |
| Baseline power of theta oscillations predicts mystical-type experiences induced by DMT | 2021 | Experimental study |
Citations in the library
Cited by 538
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Long-term follow-up of psilocybin-facilitated smoking cessation The American Journal of Drug and Alcohol Abuse July 21, 2016
- Global Street Food: la cocina de la calle Diseño interior 2009
- Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences Journal of Psychopharmacology August 31, 2016
and 533 more in the library
Cites 12
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study Journal of Psychopharmacology January 13, 2015
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology December 1, 2011
- Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Journal of Psychopharmacology September 11, 2014
- Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness Journal of Psychopharmacology September 28, 2011
and 7 more in the library